title: Follow-up experience using histidine-tryptophan ketoglutarate solution in clinical pancreas transplantation.
abstract: In May 2003, at Indiana University, the standard cold preservation solution University of Wisconsin (UW) solution was replaced by histidine-tryptophan ketogluatarate (HTK) solution. Earlier, we presented our initial experience with HTK in pancreas preservation with an analysis of the first 10 pancreas transplants. Here we report updated results with HTK in pancreas transplantation over the past 18 months. Between May 2003 and March 2005, a total of 87 pancreas transplants were performed with 78 of these organs utilizing HTK. Seventy five patients received 78 organ transplants. Surgical procedures performed were: simultaneous kidney pancreas transplantation (n = 50, 64%), pancreas after kidney transplantation (n = 19, 24%), solitary pancreas transplantation (n = 9, 12%). Donor and recipient data were collected with primary outcomes as primary nonfunction and 30-day graft and patient survivals, and compared to the UW cohort from our original report. Donor and recipient demographics were similar. Mean follow-up time is 12 +/- 6 months. The mean cold ischemia time was 9 +/- 3 hours. There were no cases of primary graft nonfunction. Thirty-day and 1-year patient survivals were 99% and 93%. The 30-day and 1-year graft survivals were 96% and 93%. There were five grafts lost, including three within the first month (two venous and one arterial thrombosis). There was one case of chronic rejection and one noncompliance. All other patients were insulin-independent by discharge. Serum fasting blood glucose and serial amylase remained comparable at all intervals posttransplantation. Within this range of cold ischemia time, HTK appears to provide effective pancreas preservation.
authors.affiliation: Department of Surgery, Indiana University School of Medicine, 550 N. University Boulevard #4258, Indianapolis, IN 46202, USA.
authors.forename: A
authors.initials: A
authors.lastname: Agarwal
authors.forename: P
authors.initials: P
authors.lastname: Murdock
authors.forename: M D
authors.initials: MD
authors.lastname: Pescovitz
authors.forename: W C
authors.initials: WC
authors.lastname: Goggins
authors.forename: M L
authors.initials: ML
authors.lastname: Milgrom
authors.forename: J A
authors.initials: JA
authors.lastname: Fridell
mesh_terms: D000328:Adult; D002423:Cause of Death; D005260:Female; D005947:Glucose; D006801:Humans; D008297:Male; D008353:Mannitol; D008875:Middle Aged; D019188:Organ Preservation Solutions; D010179:Pancreas / Q000166:cytology*; D016035:Pancreas Transplantation / Q000401:mortality / Q000502:physiology*; D011189:Potassium Chloride; D011343:Procaine; D044469:Racial Groups; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: C039984:Bretschneider cardioplegic solution; D019188:Organ Preservation Solutions; D008353:Mannitol; D011343:Procaine; D011189:Potassium Chloride; D005947:Glucose